C WorldWide Group Holding A S Trims Stake in Krystal Biotech, Inc. $KRYS

Key Points

• C WorldWide Group Holding A/S reduced its Krystal Biotech stake by 14.7% in the second quarter, selling 10,000 shares and retaining 57,809 shares worth approximately $21.5 million. Institutional investors collectively own 86.29% of KRYS.
• Krystal Biotech reported quarterly EPS of $1.79, exceeding the $1.70 consensus estimate, while revenue of $119.22 million fell slightly short of expectations. Analysts maintain a “Moderate Buy” consensus with an average price target of $365.40.
• KRYS opened at $351.26, near its 52-week high of $382.54, after substantial gains in its moving averages. Insiders have sold 51,000 shares worth approximately $17.6 million over the past 90 days.

C WorldWide Group Holding A S lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 14.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,809 shares of the company's stock after selling 10,000 shares during the period. C WorldWide Group Holding A S owned 0.20% of Krystal Biotech worth $21,486,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in KRYS. California State Teachers Retirement System boosted its position in shares of Krystal Biotech by 33,527.2% during the second quarter. California State Teachers Retirement System now owns 8,805,606 shares of the company's stock valued at $3,272,780,000 after purchasing an additional 8,779,420 shares in the last quarter. BlackRock Inc. purchased a new position in Krystal Biotech during the second quarter valued at $1,554,113,000. William Blair Investment Management LLC purchased a new position in Krystal Biotech during the second quarter valued at $211,909,000. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock valued at $126,870,000 after buying an additional 481,200 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Krystal Biotech during the 4th quarter valued at $70,159,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Price Performance

KRYS opened at $351.26 on Wednesday. The firm has a market cap of $10.40 billion, a PE ratio of 44.02 and a beta of 0.54. The stock has a 50-day moving average price of $349.01 and a 200-day moving average price of $308.57. Krystal Biotech, Inc. has a 1 year low of $136.73 and a 1 year high of $382.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company's stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Thomas sold 1,000 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 51,000 shares of company stock worth $17,558,270. Corporate insiders own 13.10% of the company's stock.

Analysts Set New Price Targets

KRYS has been the subject of several research reports. Citigroup increased their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. TD Cowen boosted their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a "buy" rating in a research note on Thursday, June 18th. Wall Street Zen cut shares of Krystal Biotech from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. HC Wainwright raised their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a "buy" rating in a research note on Tuesday, June 16th. Finally, Weiss Ratings cut Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $365.40.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.